Wall Street analysts forecast that Edwards Lifesciences (EW) will report quarterly earnings of $0.62 per share in its upcoming release, pointing to a year-over-year decline of 11.4%. It is anticipated ...

Edwards Lifesciences EW is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform is positioned for continued ...

Edwards Lifesciences Corp., the second largest public company in Orange County, is looking to expand its headquarters again.

PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first ...

Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry Provided by GlobeNewswire Jul 2, 2025, 1:09:00 PM ...

Shares of Edwards Lifesciences Corp. EW shed 1.32% to $77.18 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA ...

Edwards Lifesciences (NYSE:EW) experienced a 7.91% price increase over the last quarter, amidst significant developments. On June 30, 2025, the company was removed from several Russell indices ...

Edwards Lifesciences (EW) is a global leader in structural heart therapies, generating 60% of its revenue internationally and maintaining a focused mission on treating advanced cardiovascular disease.

MISSISSAUGA, ON, June 23, 2025 /CNW/ - Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health Canada's approval for the treatment ...